Decoding Pfizer's Options Activity: What's the Big Picture?

Investors with a lot of money to spend have taken a bearish stance on Pfizer PFE.

And retail traders should know.

We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.

Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with PFE, it often means somebody knows something is about to happen.

Today, Benzinga's options scanner spotted 13 options trades for Pfizer.

This isn't normal.

The overall sentiment of these big-money traders is split between 46% bullish and 53%, bearish.

Out of all of the options we uncovered, there was 1 put, for a total amount of $34,500, and 12, calls, for a total amount of $518,509.

Projected Price Targets

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $20.0 and $35.0 for Pfizer, spanning the last three months.

Analyzing Volume & Open Interest

Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Pfizer's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Pfizer's substantial trades, within a strike price spectrum from $20.0 to $35.0 over the preceding 30 days.

Pfizer Call and Put Volume: 30-Day Overview

Significant Options Trades Detected:

About Pfizer

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.

In light of the recent options history for Pfizer, it's now appropriate to focus on the company itself. We aim to explore its current performance.

Pfizer's Current Market Status

• With a volume of 14,872,921, the price of PFE is down -0.89% at $27.88.
• RSI indicators hint that the underlying stock may be approaching overbought.
• Next earnings are expected to be released in 46 days.

Expert Opinions on Pfizer

Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $42.0.

• Reflecting concerns, an analyst from Guggenheim lowers its rating to Buy with a new price target of $36.
• An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $45.
• In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $45.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Pfizer options trades with real-time alerts from Benzinga Pro.